Home › NDC Lookup › Ingredients › Sodium Chloride › 00990-7983-02
Sodium Chloride 900 mg/100mL Injection, Solution — NDC 00990-7983-02 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Sodium Chloride 900 mg/100mL Injection, Solution — NDC 0990-7983-02 (Billing 00990-7983-02)

by ICU Medical Inc. · 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 250 mL in 1 BAG

This is a package of Sodium Chloride 900 mg/100mL Injection, Solution from ICU Medical Inc., marketed since Apr 2019 and currently FDA-listed.

NDC 00990-7983-02
🏷️ FDA NDC (as labeled) 0990-7983-02 billing pads the labeler segment with a zero
This package
Contains250 mL in 1 bag Medicaid pays$0.5667 / unit · 12 mo Per package$3,400.20 / 6000 ml · Medicaid Pack sizes6 compare ↓
Also priced by: Part D plans $0.0121/unit — full pricing hub ↓
Product page 00990-7983-09 Also comes in: 12 pouches 0990-7983-09 18 pouches 0990-7983-55 24 pouches 0990-7983-03 24 pouches 0990-7983-53 32 pouches 0990-7983-61
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0990-7983-02 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0990 labeler · 7983 product · 02 package
Package marketed since
May 1, 2019
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0990798302 8
Medicaid fills, this package
29,032 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
🚨
Active recall for this product.
Class II · Oct 27, 2025 — Lack of Assurance of Sterility: Potential for flexible container leaks. (Otsuka ICU Medical LLC) · FDA recall D-0143-2026
Lots / codes: Lot # 1029921, Exp Date: 28 February 2027 · reported Nov 5, 2025
Class II · Nov 9, 2022 — Lack of assurance of sterility: Bags have the potential to leak in the flexible containers which may compromise sterility. (ICU Medical Inc) · FDA recall D-0062-2023
Lots / codes: Lot: 5829936, Exp. MAR 31 2024 · reported Nov 23, 2022
Check your lot/expiration against the official notice — look up the recall number in the FDA recall database ↗
⚠️
Other active recalls for Sodium Chloride (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class I · Aug 17, 2026 — Presence of particulate matter: Particulates identified as fiberglass (Baxter Healthcare Corporation) · FDA recall D-0849-2026
Class II · Apr 2, 2026 — Lack of Assurance of Sterility (Huons Co., Ltd.) · FDA recall D-0531-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0427-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0424-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0432-2026
Class II · Mar 11, 2026 — Lack of Assurance of Sterility (Fresenius Kabi USA, LLC) · FDA recall D-0426-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0990-7983-02
Product NDC 0990-7983
11-digit billing NDC 00990798302
NCPDP billing unit ML — per mL (volume)
RxCUI 1807548, 1807549, 1807550, 1807551, 1807552, 1807627, 1807630, 1807631,
UNII 451W47IQ8X
Application # NDA016366
SPL Set ID 5f372b75-d7a4-471e-8ac6-290040fc84b0
Established class (EPC) Osmotic Laxative
Mechanism of action Osmotic Activity
Physiologic effect Increased Large Intestinal Motility; Inhibition Large Intestine Fluid/Electrolyte Absorption
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2019-04-01
Route INTRAVENOUS
Dosage form INJECTION, SOLUTION
Substance SODIUM CHLORIDE
TE code (Orange Book) AP · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 79750010002021
GPI class Sodium Chloride
GCN Seq No 001210
GCN 02962
HICL code 008255
Ingredient (HICL) 0.9 % Sodium Chloride
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C1
Therapeutic class — intermediate (HIC2) Drugs Affecting Electrolyte Balance
HIC3 code C1B
Therapeutic class — specific (HIC3) Sodium/Saline Preparations
AHFS code 40:12.00.00
AHFS class Replacement Preparations
FDB label name SODIUM CHLORIDE 0.9% SOLUTION
FDB brand name Sodium Chloride
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001210
  • GCN: 02962
  • GPI-14 (Medi-Span): 79750010002021
  • HICL (First Databank): 008255
  • AHFS class code: 40:12.00.00
  • RxCUI (RxNorm): 1807548
Why two NDCs? The FDA registers this code as 0990-7983-02 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00990-7983-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Sodium class.

Drug family (ATC) Sodium, Salt solutions, Electrolyte solutions
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name SODIUM CHLORIDE 0.9% SOLUTION Ingredient 0.9 % Sodium Chloride
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. IV forms replace fluid and salt, while injection diluents dissolve other drugs. Other forms are used for rinsing, nasal congestion and nasal care, or to...
  • Follow the directions on your product. Many are used as often as needed by adults and children 4 and over. Do not share the bottle, because that can spread infection.
  • Some people get fever, irritation or infection at the IV site, or too much fluid in the body. Tell your nurse right away if the IV site hurts or looks red.
  • What side effects should I expect with IV sodium chloride?
📖 Read our full Sodium Chloride guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo $0.5667 $3,400.20 / 6000 ml
Medicare drug plans payPart D · Q2 2026 $0.0121 $72.60 / 6000 ml
Medicare Part B allowsASP · J7050 $0.703 / J7050 unit —
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0990-7983-02
11-digit billing NDC00990-7983-02
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ7050
DescriptorINFUSION, NORMAL SALINE SOLUTION , 250 CC
Billing units / pkg0 units
How the units are derivedThis package is 250 ML; the HCPCS unit is 250 ML, so one package = 0 billing units.
Medicare Part B spend (2026 (Q1))$71,508 · 73,055 claims · $0.98 per claim (all NDCs under J7050)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00990-7983-02 You're viewing this 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 250 mL in 1 BAG 2019-05-01 — Active
00990-7983-03 0990-7983-03 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 500 mL in 1 BAG 2019-12-31 — Active
00990-7983-09 0990-7983-09 Main listing 12 POUCH in 1 CASE / 1 BAG in 1 POUCH / 1000 mL in 1 BAG 2019-11-15 — Active
00990-7983-53 0990-7983-53 24 POUCH in 1 CASE / 1 BAG in 1 POUCH / 250 mL in 1 BAG 2019-12-31 — Active
00990-7983-55 0990-7983-55 18 POUCH in 1 CASE / 1 BAG in 1 POUCH / 500 mL in 1 BAG 2019-12-31 — Active
00990-7983-61 0990-7983-61 32 POUCH in 1 CASE / 1 BAG in 1 POUCH / 150 mL in 1 BAG 2019-11-01 — Active

This pack accounts for about 9.6% of this product's recent Medicaid fills; most go to a different pack size. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 24 pouch in 1 case / 1 bag in 1 pouch / 250 ml in 1 bag.
What NDC number is used to bill for this package of Sodium Chloride 900 mg/100mL Injection, Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Sodium Chloride 900 mg/100mL 00409-7101-02 Hospira, 24 pouches $0.021 AP Discontinued —
Sodium Chloride 900 mg/100mL 51662-1522-01 HF 500 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-0186-04 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-0162-01 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00990-7984-13 ICU 48 pouches — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-0196-04 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-9159-30 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-0166-01 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-9662-35 Baxter 100 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 00338-0553-11 Baxter 50 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 46163-0300-10 Fresenius 1000 ml — AP FDA listed —
Sodium Chloride 900 mg/100mL 49230-0300-10 Fresenius 1000 ml — AP FDA listed —
Sodium Chloride 900 mg/100mLthis 00990-7983-02 ICU 24 pouches — AP FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2019
On the market since
Apr 2019
📍
2026
Currently FDA-listed
7 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerICU Medical Inc.
Application holderOTSUKA ICU MEDICAL LLC
FDA applicationNDA016366 (NDA)
Labeler code00990
First marketedApr 2019
Product typeHuman Prescription Drug
Portfolio48 products on file

More NDCs from ICU Medical Inc. labeler code 00990

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 27 words ▾

INDICATIONS AND USAGE Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient.

⏱️ Dosage and Administration 61 words ▾

DOSAGE AND ADMINISTRATION The dose is dependent upon the age, weight and clinical condition of the patient. Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS .)

⛔ Contraindications 3 words ▾

CONTRAINDICATIONS None known.

⚠️ Warnings 117 words ▾

WARNINGS Sodium Chloride Injection, USP should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. The intravenous administration of Sodium Chloride Injection, USP can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutive states is inversely proportional to the electrolyte concentration of the injections.

The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections. In patients with diminished renal function, administration of Sodium Chloride Injection, USP may result in sodium retention.

🤒 Adverse Reactions 87 words ▾

ADVERSE REACTIONS Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary. In addition to the above listed adverse reactions hyponatremia has been reported for 0.45% Sodium Chloride Injection, USP (see Pediatric Use section).

🔄 Drug Interactions ~2 min read ▾

DRUG INTERACTIONS Caution must be exercised in the administration of Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP.

It is also not known whether Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection, USP should be given to a pregnant woman only if clearly needed. Labor and Delivery Studies have not been conducted to evaluate the effects of Sodium Chloride Injection, USP on labor and delivery.

Caution should be exercised when administering this drug during labor and delivery. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sodium Chloride Injection, USP is administered to a nursing mother.

Pediatric Use The use of Sodium Chloride Injection, USP in pediatric patients is based on clinical practice. Plasma electrolyte concentrations should be closely monitored in the pediatric population as this population may have impaired ability to regulate fluids and electrolytes. The infusion of hypotonic fluids (0.45% Sodium Chloride Injection, USP) together with the non-osmotic secretion of ADH may result in hyponatremia in patients with acute volume depletion.

Hyponatremia can lead to headache, nausea, seizures, lethargy, coma, cerebral edema and death, therefore acute symptomatic hyponatremic encephalopathy is considered a medical emergency. Geriatric Use Clinical studies of Sodium Chloride Injection, USP did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Do not administer unless solution is clear and container is undamaged. Discard unused portion.

🆘 Overdosage 26 words ▾

OVERDOSAGE In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .)

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY When administered intravenously, these solutions provide a source of water and electrolytes. Solutions which provide combinations of hypotonic or isotonic concentrations of sodium chloride are suitable for parenteral maintenance or replacement of water and electrolyte requirements. Isotonic concentrations of sodium chloride are suitable for parenteral replacement of chloride losses that exceed or equal the sodium loss.

Hypotonic concentrations of sodium chloride are suited for parenteral maintenance of water requirements when only small quantities of salt are desired. A hypertonic concentration of sodium chloride may be used to repair severe salt depletion syndrome. Sodium chloride in water dissociates to provide sodium (Na + ) and chloride (Cl − ) ions.

Sodium (Na + ) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Chloride (Cl − ) has an integral role in buffering action when oxygen and carbon dioxide exchange occurs in the red blood cells. The distribution and excretion of sodium (Na + ) and chloride (Cl − ) are largely under the control of the kidney which maintains a balance between intake and output.

Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirements range from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production). Water balance is maintained by various regulatory mechanisms.

Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na + ) plays a major role in maintaining physiologic equilibrium.

📦 How Supplied / Storage and Handling ~1 min read ▾

HOW SUPPLIED Sodium Chloride Injection, USP is supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table. NDC No. Product Container size mL 0409-7730-36 Manufactured by ICU Medical, Inc., Lake Forest, Illinois, 60045, USA 0.45% Sodium Chloride Inj., USP 50 0990-7730-36 0.45% Sodium Chloride Inj., USP 50 0409-7730-37 0.45% Sodium Chloride Inj., USP 100 0990-7730-37 0.45% Sodium Chloride Inj., USP 100 0409-7985-02 0.45% Sodium Chloride Inj., USP 250 0990-7985-02 0.45% Sodium Chloride Inj., USP 250 0409-7985-03 Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA 0.45% Sodium Chloride Inj., USP 500 0990-7985-03 , 0.45% Sodium Chloride Inj., USP 500 0409-7985-09 , 0.45% Sodium Chloride Inj., USP 1000 0990-7985-09 , 0.45% Sodium Chloride Inj., USP 1000 0409-7984-20 0.9% Sodium Chloride Inj., USP 25 0990-7984-20 0.9% Sodium Chloride Inj., USP 25 0409-7984-36 0.9% Sodium Chloride Inj., USP 50 0990-7984-36 0.9% Sodium Chloride Inj., USP 50 0409-7984-13 0.9% Sodium Chloride Inj., USP 50 0990-7984-13 0.9% Sodium Chloride Inj., USP 50 0409-7984-37 0.9% Sodium Chloride Inj., USP 100 0990-7984-37 0.9% Sodium Chloride Inj., USP 100 0409-7984-23 0.9% Sodium Chloride Inj., USP 100 0990-7984-23 0.9% Sodium Chloride Inj., USP 100 0409-7983-61 0.9% Sodium Chloride Inj., USP 150 0990-7983-61 0.9% Sodium Chloride Inj., USP 150 0409-7983-02 , 0.9% Sodium Chloride Inj., USP 250 0990-7983-02 , 0.9% Sodium Chloride Inj., USP 250 0409-7983-53 0.9% Sodium Chloride Inj., USP 250 0990-7983-53 0.9% Sodium Chloride Inj., USP 250 0409-7983-03 0.9% Sodium Chloride Inj., USP 500 0990-7983-03 , 0.9% Sodium Chloride Inj., USP 500 0409-7983-55 0.9% Sodium Chloride Inj., USP 500 0990-7983-55 0.9% Sodium Chloride Inj., USP 500 0409-7983-09 , 0.9% Sodium Chloride Inj., USP 1000 0990-7983-09 , 0.9% Sodium Chloride Inj., USP 1000 ICU Medical is transitioning NDC codes from "0409" to "0990" labeler code.

Both NDC codes are expected to be in the market for a period of time. Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Revised: April, 2020 IFU0000188

📋 Description ~1 min read ▾

DESCRIPTION Sodium Chloride Injection, USP solutions are sterile and nonpyrogenic. They are parenteral solutions containing various concentrations of sodium chloride in water for injection intended for intravenous administration. For 0.45% Sodium Chloride Injection, USP, each 100 mL contains 450 mg sodium chloride in water for injection.

Electrolytes per 1000 mL: sodium 77 mEq; chloride 77 mEq. The osmolarity is 154 mOsmol/L (calc.). For 0.9% Sodium Chloride Injection, USP, each 100 mL contains 900 mg sodium chloride in water for injection.

Electrolytes per 1000 mL: sodium 154 mEq; chloride 154 mEq. The osmolarity is 308 mOsmol/L (calc.). The pH for both concentrations in the 100 mL and smaller containers is 6.0; for the 250 mL and larger containers, the pH is 5.6.

The pH range is 4.5 to 7.0 for all containers. The solutions contain no bacteriostat, antimicrobial agent or added buffer and each is intended only as a single-dose injection. When smaller doses are required the unused portion should be discarded.

The solutions are parenteral fluid and electrolyte replenishers. Sodium Chloride, USP is chemically designated NaCl, a white crystalline powder freely soluble in water. Water for Injection, USP is chemically designated H 2 O.

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

Exposure to temperatures above 25°C (77°F) during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

⚠️ Precautions 142 words ▾

PRECAUTIONS General Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. Pressurizing intravenous solutions contained in flexible plastic containers to increase flow rates can result in air embolism if the residual air in the container is not fully evacuated prior to administration.

Use of a vented intravenous administration set with the vent in the open position could result in air embolism. Vented intravenous administration sets with the vent in the open position should not be used with flexible plastic containers. Laboratory Tests Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.

📄 Package Label / Principal Display Panel ~2 min read ▾

PRINCIPAL DISPLAY PANEL - 50 mL Bag Label 50 mL NDC 0990-7730-36 0.45% SODIUM CHLORIDE INJECTION, USP EACH 100 mL CONTAINS SODIUM CHLORIDE 450 mg IN WATER FOR INJECTION. ELECTROLYTES PER 1000 mL: SODIUM 77 mEq; CHLORIDE 77 mEq. 154 mOsmol/LITER (CALC.) pH 6.0 (4.5 to 7.0) ADDITIVES MAY BE INCOMPATIBLE.

CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE-DOSE CONTAINER.

FOR INTRAVENOUS USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC.

USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 3 v CONTAINS DEHP IM-4346 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical PRINCIPAL DISPLAY PANEL - 50 mL Bag Label

PRINCIPAL DISPLAY PANEL - 250 mL Bag Label 250 mL NDC 0990-7983-53 0.9% SODIUM CHLORIDE INJECTION, USP EACH 100 mL CONTAINS SODIUM CHLORIDE 900 mg IN WATER FOR INJECTION. ELECTROLYTES PER 1000 mL: SODIUM 154 mEq; CHLORIDE 154 mEq. 308 mOsmol/LITER (CALC). pH 5.6 (4.5 to 7.0) ADDITIVES MAY BE INCOMPATIBLE.

CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE-DOSE CONTAINER.

FOR INTRAVENOUS USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC.

USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 3 v CONTAINS DEHP IM-4450 Manufactured for ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical PRINCIPAL DISPLAY PANEL - 250 mL Bag Label

PRINCIPAL DISPLAY PANEL - 25 mL Bag Label 25 mL NDC 0990-7984-20 0.9% SODIUM CHLORIDE Injection, USP EACH 100 mL CONTAINS SODIUM CHLORIDE, 900 mg. ELECTROLYTES (mEq/LITER): SODIUM, 154 mEq; CHLORIDE, 154 mEq. 308 mOsmol/LITER (CALC). pH 6.0 (4.5 to 7.0).

ADDITIVES MAY BE INCOMPATIBLE. SINGLE-DOSE CONTAINER. FOR I.V.

USE. USUAL DOSAGE: SEE INSERT. STERILE, NONPYROGENIC.

USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS. Rx ONLY 3 v CONTAINS DEHP ICU Medical, Inc., Lake Forest, Illinois, 60045, USA icumedical IM-4350 PRINCIPAL DISPLAY PANEL - 25 mL Bag Label

PRINCIPAL DISPLAY PANEL - 500 mL Bag Label 500 mL NDC 0990-7985-03 0.45% Sodium Chloride Injection, USP EACH 100 mL CONTAINS SODIUM CHLORIDE 450 mg IN WATER FOR INJECTION. ELECTROLYTES PER 1000 mL: SODIUM 77 mEq; CHLORIDE 77 mEq. 154 mOsmol/LITER (CALC.) pH 5.6 (4.5 to 7.0) ADDITIVES MAY BE INCOMPATIBLE.

CONSULT WITH PHARMACIST, IF AVAILABLE. WHEN INTRODUCING ADDITIVES, USE ASEPTIC TECHNIQUE, MIX THOROUGHLY AND DO NOT STORE. SINGLE-DOSE CONTAINER.

FOR I.V. USE. USUAL DOSAGE: SEE INSERT.

STERILE, NONPYROGENIC. USE ONLY IF SOLUTION IS CLEAR AND CONTAINER IS UNDAMAGED. MUST NOT BE USED IN SERIES CONNECTIONS.

Rx ONLY 3 v CONTAINS DEHP icumedical IM-4391 ICU Medical, Inc., Lake Forest, Illinois, 60045, USA PRINCIPAL DISPLAY PANEL - 500 mL Bag Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
29K
Units reimbursed last 4 qtrs
8.9M
Gross reimbursed last 4 qtrs
$5.04M
Avg / prescription
$173.68
Avg / unit
$0.5667
Latest quarter Q4 2025
6KRx
Fee-for-service vs managed care ⓘ
23% FFS 77% MCO
Fee-for-service · 6,661 Rx Managed care · 22,371 Rx
State Medicaid map
Alaska: no data reported AK Maine: 121,000 units · 8,674 per 100k residents ME Washington: 61 units · 0.8 per 100k residents WA Idaho: 540,750 units · 27,533 per 100k residents ID Montana: 761 units · 67.2 per 100k residents MT North Dakota: 67,251 units · 8,589 per 100k residents ND Minnesota: 216,001 units · 3,765 per 100k residents MN Wisconsin: 138,000 units · 2,335 per 100k residents WI Michigan: no data reported MI New York: 1,010,250 units · 5,162 per 100k residents NY Vermont: 7,750 units · 1,198 per 100k residents VT New Hampshire: 16,912 units · 1,206 per 100k residents NH Oregon: 309,000 units · 7,300 per 100k residents OR Nevada: 39,000 units · 1,221 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 429,000 units · 13,377 per 100k residents IA Illinois: no data reported IL Indiana: 388,170 units · 5,657 per 100k residents IN Ohio: 270,000 units · 2,291 per 100k residents OH Pennsylvania: 110,000 units · 849 per 100k residents PA New Jersey: no data reported NJ Massachusetts: 1,120 units · 16.0 per 100k residents MA California: 1,258,083 units · 3,229 per 100k residents CA Utah: no data reported UT Colorado: 6,000 units · 102 per 100k residents CO Nebraska: 286,250 units · 14,472 per 100k residents NE Missouri: 194,750 units · 3,143 per 100k residents MO Kentucky: 1,848,892 units · 40,850 per 100k residents KY West Virginia: 20,750 units · 1,172 per 100k residents WV Virginia: 180,751 units · 2,074 per 100k residents VA Maryland: 16,253 units · 263 per 100k residents MD Connecticut: 100,751 units · 2,785 per 100k residents CT Rhode Island: no data reported RI Arizona: 89,500 units · 1,204 per 100k residents AZ New Mexico: 75,250 units · 3,560 per 100k residents NM Kansas: 48,750 units · 1,658 per 100k residents KS Arkansas: no data reported AR Tennessee: 60,250 units · 845 per 100k residents TN North Carolina: 71,615 units · 661 per 100k residents NC South Carolina: 37,250 units · 693 per 100k residents SC Delaware: no data reported DE Oklahoma: 234,500 units · 5,786 per 100k residents OK Louisiana: no data reported LA Mississippi: 16,251 units · 553 per 100k residents MS Alabama: 48,000 units · 940 per 100k residents AL Georgia: 195,250 units · 1,770 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 344,000 units · 1,128 per 100k residents TX Florida: 100,250 units · 443 per 100k residents FL
Units reimbursed · per 100k residents
0.840,850
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kentucky 40,850 /100k
2 Idaho 27,533 /100k
3 Nebraska 14,472 /100k
4 Iowa 13,377 /100k
5 Maine 8,674 /100k
6 North Dakota 8,589 /100k
7 Oregon 7,300 /100k
8 Oklahoma 5,786 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
12 pouches00990-7983-09 230,418 Rx · $11,274,465
24 pouches00990-7983-03 30,673 Rx · $4,253,853
24 pouches this page00990-7983-02 29,032 Rx · $5,042,402
32 pouches00990-7983-61 7,162 Rx · $398,841
18 pouches00990-7983-55 3,714 Rx · $246,891
24 pouches00990-7983-53 No Medicaid data
Drug total (last 4 qtrs): 300,999 Rx · 327,824,037 units · $21,216,451 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Sodium Chloride — the program that covers self-administered drugs. 9 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Sodium Chloride. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.42M
Claims incl. refills
105K
Beneficiaries
50.3K
Spend / beneficiary
$48.15
Spend / claim
$23.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk ✓ Available
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by ICU Medical Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 5 other package presentations of this same product, including 12 pouches (00990-7983-09), 18 pouches (00990-7983-55), 24 pouches (00990-7983-03). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
ICU Medical Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
Does this product have a billing J-code?
Yes — this NDC cross-references HCPCS code J7050 for medical-claim billing (typically used when a product is administered in a clinical setting rather than dispensed at a retail pharmacy). See the Billing section on this page.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00990-7982-09 · ICU 00990-7984-13 · ICU →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.